Atyr PHARMA INC (NASDAQ:ATYR) Short Interest Update

Atyr PHARMA INC (NASDAQ:ATYR - Get Free Report) saw a large increase in short interest in February. As of February 28th, there was short interest totalling 5,260,000 shares, an increase of 20.9% from the February 13th total of 4,350,000 shares. Based on an average daily trading volume, of 1,140,000 shares, the days-to-cover ratio is currently 4.6 days. Approximately 6.5% of the company's stock are sold short.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. Leerink Partnrs upgraded shares of Atyr PHARMA to a "strong-buy" rating in a report on Tuesday, February 18th. Cantor Fitzgerald began coverage on shares of Atyr PHARMA in a research report on Monday, January 6th. They issued an "overweight" rating on the stock. HC Wainwright reissued a "buy" rating and issued a $35.00 price objective on shares of Atyr PHARMA in a research report on Friday, March 14th. Finally, Leerink Partners began coverage on shares of Atyr PHARMA in a research report on Tuesday, February 18th. They issued an "outperform" rating and a $16.00 price objective on the stock. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $18.60.

Atyr PHARMA Stock Down 2.1 %

Shares of NASDAQ:ATYR traded down $0.08 during trading hours on Friday, reaching $3.68. The stock had a trading volume of 819,703 shares, compared to its average volume of 844,478. Atyr PHARMA has a 1 year low of $1.42 and a 1 year high of $4.66. The firm's 50 day moving average is $3.66 and its 200-day moving average is $3.13. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.41 and a current ratio of 5.41. The stock has a market capitalization of $327.00 million, a price-to-earnings ratio of -3.91 and a beta of 0.98.

Remove Ads

Atyr PHARMA (NASDAQ:ATYR - Get Free Report) last announced its quarterly earnings results on Thursday, March 13th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.05. Research analysts predict that Atyr PHARMA will post -0.91 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Atyr PHARMA

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Group One Trading LLC acquired a new stake in Atyr PHARMA during the 4th quarter worth $26,000. Alterna Wealth Management Inc. acquired a new stake in Atyr PHARMA during the 4th quarter worth $36,000. Victory Capital Management Inc. acquired a new stake in Atyr PHARMA during the 4th quarter worth $37,000. Raymond James Financial Inc. acquired a new stake in Atyr PHARMA during the 4th quarter worth $39,000. Finally, JPMorgan Chase & Co. raised its stake in Atyr PHARMA by 52.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 31,440 shares of the company's stock worth $55,000 after acquiring an additional 10,754 shares in the last quarter. 61.72% of the stock is currently owned by institutional investors and hedge funds.

About Atyr PHARMA

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.